CAMBRIDGE, Mass., April 22, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ('NeuroSense'), a company developing novel treatments for severe neurodegenerative diseases announced today a collaboration in Alzheimer's Disease (AD) drug development with Genetika+, a leader in precision medicine for psychiatry and neurology.

马萨诸塞州剑桥，2024年4月22日/PRNewswire/--NeuroSense Therapeutics Ltd.（纳斯达克：NRSN）（“NeuroSense”）是一家开发严重神经退行性疾病新型治疗方法的公司，今天宣布与精神病学和神经病学精准医学领军者Genetika+合作开发阿尔茨海默病（AD）药物。

The multi-phase collaboration, which will commence in NeuroSense's currently ongoing Phase 2 AD clinical trial, leverages Genetika+'s state-of-the-art technology that derives frontal cortex neurons from individual patients' blood to quantify drug-induced neuronal plasticity in vitro..

该多阶段合作将从NeuroSense目前正在进行的2期AD临床试验开始，利用Genetika+的最新技术，从个体患者的血液中提取额叶皮层神经元，以量化药物诱导的神经元可塑性。。

The Genetika+ technology serves as a human AD disease model and will be used to correlate clinical response with cellular effects, for mechanistic drug insights and patient subset identification, supporting drug development and potentially commercialization. This collaboration addresses key challenges in the development of drugs for AD, by promoting disease and drug mechanistic understanding, increasing the likelihood of success of AD drug development, and enabling the realization of precision medicine approaches. .

Genetika+技术可作为人类AD疾病模型，将用于将临床反应与细胞效应相关联，用于机械药物见解和患者亚群鉴定，支持药物开发和潜在的商业化。这种合作通过促进疾病和药物机制的理解，增加AD药物开发成功的可能性，以及实现精准医学方法，解决了AD药物开发中的关键挑战。。

'We believe Genetika+'s technology presents a unique opportunity to optimize our current ongoing trial. It harmonizes seamlessly with our evaluation of our combination drug therapy through clinical assessments and an extensive array of biomarkers,' stated Dr. Shiran Zimri, VP of R&D at NeuroSense. 'There are significant opportunities to harness cutting-edge advancements in AD therapeutic research and these are crucial for the future of early detection and treatment of neurodegenerative conditions.'.

“我们相信Genetika+的技术为优化我们目前正在进行的试验提供了一个独特的机会。NeuroSense研发副总裁Shiran Zimri博士表示，它与我们通过临床评估和广泛的生物标志物对联合药物治疗的评估无缝协调利用AD治疗研究的前沿进展有着重要的机会，这些对于神经退行性疾病的早期发现和治疗的未来至关重要。”。

Distinguished by its innovative approach, NeuroSense's PrimeC therapy stands out in the landscape of AD treatments. Unlike conventional methods that predominantly target amyloid-beta (Aβ), PrimeC adopts a multi-targeted strategy, concurrently addressing Aβ aggregation, TDP-43, and other key disease-related pathologies.

凭借其创新的方法，NeuroSense的PrimeC疗法在AD治疗领域脱颖而出。与主要靶向淀粉样蛋白β（Aβ）的常规方法不同，PrimeC采用多靶向策略，同时解决Aβ聚集，TDP-43和其他关键的疾病相关病理。

This unique approach not only diversifies the therapeutic targets but also offers the potential for more potent treatment outcomes. With a well demonstrated synergistic mode of action, compelling pre-clinical and clinical data in related filed, and a strong safety profile, PrimeC is poised to potentially provide therapeutic efficacy in AD..

这种独特的方法不仅使治疗靶点多样化，而且为更有效的治疗结果提供了潜力。凭借良好的协同作用模式，相关领域令人信服的临床前和临床数据以及强大的安全性，PrimeC有望在AD中提供潜在的治疗效果。。

'This partnership represents a critical step forward in the fight against Alzheimer's Disease,' said Daphna Laifenfeld, co-founder and CSO at Genetika+. 'By combining our leading-edge technologies, we anticipate the possibility of both bring efficacious therapies to patients sooner, and to moving beyond a one-size-fits-all approach to AD treatment and unlock the potential for personalized, targeted therapies that significantly improve patient outcomes.'.

Genetika+的联合创始人兼CSO Daphna Laifenfeld说，“这种合作关系代表着在抗击阿尔茨海默氏病方面迈出了关键的一步。”通过结合我们的前沿技术，我们预计两者都有可能更快地为患者带来有效的治疗方法，并超越一刀切的AD治疗方法，并释放个性化，靶向治疗的潜力，从而显着改善患者预后。”。

Currently enrolling at the Stroke and Cognition Institute, Rambam Health Care Campus, Haifa, Israel, RoAD, NeuroSense's Phase 2 randomized, prospective double-blind, placebo-controlled study is designed to evaluate the therapeutic potential of PrimeC in treating AD. The study will consist of 20 patients with mild to moderate non-familial AD.

目前正在以色列海法Rambam Health Care Campus中风与认知研究所注册，RoAD，NeuroSense的2期随机，前瞻性双盲，安慰剂对照研究旨在评估PrimeC治疗AD的治疗潜力。该研究将由20名轻度至中度非家族性AD患者组成。

Participants will receive PrimeC or placebo (1:1) twice daily for 12 months and will be evaluated every three months. Endpoints include clinical outcome measurements, AD-related biomarkers, and markers of target engagement extracted from plasma and cerebrospinal fluid (CSF). The study is expected to reveal the safety of PrimeC in AD, as well as shed light on the efficacy and biological activity of this combination therapy in this indication..

参与者将每天两次接受PrimeC或安慰剂（1:1），持续12个月，每三个月进行一次评估。终点包括临床结果测量，AD相关生物标志物以及从血浆和脑脊液（CSF）中提取的靶标参与标志物。该研究有望揭示PrimeC在AD中的安全性，并阐明该联合疗法在该适应症中的疗效和生物活性。。

About Genetika+

关于遗传学+

Genetika+, founded in 2018 by Talia Cohen-Solal, Ph.D., and Daphna Laifenfeld, Ph.D., is developing personalized medicine solutions to optimize treatment for psychiatric and neurological diseases. The company's proprietary AI-powered platform, Stemifai, leverages stem cell differentiation and machine learning to inform and advance CNS drug development processes.

Genetika+由Talia Cohen Solal博士和Daphna Laifenfeld博士于2018年创立，目前正在开发个性化医疗解决方案，以优化精神病和神经疾病的治疗。该公司专有的人工智能平台Stemifai利用干细胞分化和机器学习来告知和推进中枢神经系统药物开发过程。

To learn more, follow us on LinkedIn or on Twitter @Genetikaplus..

要了解更多信息，请跟随我们 LinkedIn 或者在推特上 @Genetikaplus。。

About NeuroSense

关于NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date.

NeuroSense Therapeutics，Ltd.是一家临床阶段生物技术公司，专注于为患有衰弱性神经退行性疾病的患者发现和开发治疗方法。NeuroSense认为，这些疾病，包括肌萎缩侧索硬化症（ALS），阿尔茨海默氏病和帕金森氏病等，代表了我们这个时代最重要的未满足的医疗需求之一，迄今为止，患者可用的有效治疗选择有限。

Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases..

由于神经退行性疾病的复杂性，并且基于对大量相关生物标志物的强大科学研究，NeuroSense的策略是开发针对与这些疾病相关的多种途径的联合疗法。。

For additional information, please visit the Company's website and follow NeuroSense on LinkedIn and X (Twitter).

有关更多信息，请访问该公司的网站，并在LinkedIn和X（Twitter）上关注NeuroSense。

Forward-Looking Statements

前瞻性声明

This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words.

本新闻稿包含具有重大风险和不确定性的“前瞻性声明”。除历史事实声明外，本新闻稿中的所有声明均为前瞻性声明。本新闻稿中包含的前瞻性陈述可以通过使用诸如“预期”、“相信”、“沉思”、“可能”、“估计”、“期望”、“打算”、“寻求”、“可能”、“可能”、“计划”、“潜力”、“预测”、“项目”、“目标”、“目标”、“应该”、“将会”或这些词语的否定词或其他类似表达来识别，尽管并非所有前瞻性陈述都包含这些词语。

Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding NeuroSense's collaboration with Genetika+, and the timing and results of a Phase 2 trial for Alzheimer's disease.

前瞻性陈述基于NeuroSense Therapeutics目前的预期，并受到难以预测的固有不确定性，风险和假设的影响，包括有关NeuroSense与Genetika+合作的陈述，以及阿尔茨海默病2期试验的时间和结果。

Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the risk that NeuroSense's collaboration with Genetika+ will not bring the anticipated benefits, unexpected R&D costs or operating expenses, the timing of expected regulatory and business milestones, a delay in patient enrollment for, and unanticipated results of, a Phase 2 trial for Alzheimer's disease; the potential for PrimeC to safely and effectively target AD; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes and the timing of current and future clinical trials; ti.

此外，某些前瞻性陈述基于对未来事件的假设，这些假设可能不准确。未来的事件和趋势可能不会发生，实际结果可能与前瞻性声明中预期或暗示的结果存在重大不利差异。这些风险包括NeuroSense与Genetika+的合作不会带来预期收益的风险，意外的研发成本或运营费用，预期监管和业务里程碑的时间安排，患者登记的延迟以及阿尔茨海默病2期试验的意外结果；PrimeC安全有效地针对AD的潜力；PrimeC的临床前和临床数据；目前和未来临床试验的结果和时间的不确定性；德州仪器。

Logo : https://mma.prnewswire.com/media/2386697/NRSN_GNTC_Logo.jpg

标志https://mma.prnewswire.com/media/2386697/NRSN_GNTC_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurosense-and-genetika-initiate-precision-medicine-collaboration-beginning-with-ongoing-phase-2-clinical-trial-in-alzheimers-disease-302122778.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/neurosense-and-genetika-initiate-precision-medicine-collaboration-beginning-with-ongoing-phase-2-clinical-trial-in-alzheimers-disease-302122778.html

SOURCE NeuroSense

源神经感觉

Company Codes: NASDAQ-NMS:NRSN

公司代码：NASDAQ-NMS：NRSN